Fredun Pharmaceuticals Limited Q4 FY26 earnings call summary

Earnings call of 10 Jun 2026, summarised by AI from the filing.

Management intends 25% to 30% top line growth on last year for FY27.

Key takeaways

1. FY27 guidance Management intends 25% to 30% top line growth on last year for FY27.
2. Margin change FY26 EBITDA margin 14.83%, up 276 bps; new age businesses have higher intrinsic margins.

Original filing on BSE

Fredun Pharmaceuticals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (13 Aug 2026)
• Q4 FY26: Earnings call (10 Jun 2026)
• Q3 FY26: Earnings call (12 Feb 2026)
• Q2 FY26: Earnings call (11 Nov 2025)
• Q1 FY26: Earnings call (1 Aug 2025)
• Other events: Call transcript (6 Jun 2026), Strategy deck (10 Jun 2025), Strategy deck (10 Jun 2025)